{"id":3123,"date":"2020-06-04T21:16:13","date_gmt":"2020-06-04T21:16:13","guid":{"rendered":"https:\/\/mirm-pitt.net\/technologies\/?post_type=avada_portfolio&p=3123"},"modified":"2020-07-08T09:20:50","modified_gmt":"2020-07-08T09:20:50","slug":"activators-of-cxcr3-for-the-treatment-of-angiopathies-of-the-eye-3","status":"publish","type":"avada_portfolio","link":"https:\/\/mirm-pitt.net\/technologies\/patents\/activators-of-cxcr3-for-the-treatment-of-angiopathies-of-the-eye-3\/","title":{"rendered":"Activators Of CXCR3 FOR The Treatment Of Angiopathies Of The Eye (3)"},"content":{"rendered":"

Activators Of CXCR3 FOR The Treatment Of Angiopathies Of The Eye (3)<\/h2>\n

CXCR3 Receptor Activator: Biologically Active Interferon-y-Inducible 10 kDa Protein (IP-10) Peptide Fragment Amino Acid Sequence Of SEQ ID NO: 4<\/p>\n<\/div>

<\/div><\/div><\/div>

Inventors:<\/strong> Alan H. Wells: Cecelia C. Yates: Joel Steven Schuman<\/p>\n

Patent Number:<\/strong> 14\/240,132<\/p>\n

\n
\n
\n

Abstract<\/h3>\n
\n
\n
The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of CXCR3. In some embodiments, the activator of CXCR3 is IP-10 or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal \u03b1-helix of IP-10. In other embodiments, the activator of CXCR3 is PF4 or a fragment or variant thereof.<\/div>\n<\/section>\n<\/div>\n<\/section>\n<\/div>\n<\/div>\n<\/div>
<\/div>
<\/div>
<\/div>